SDS Optic

SDS Optic is a publicly traded Polish medtech company with a mission to address unmet diagnostic needs in oncology and infectious diseases through its proprietary inPROBE fiber-optic biosensor platform. The company has completed a clinical investigation for HER2 detection in breast cancer and maintains a diversified business model combining long-term R&D with near-term service revenue from antibody manufacturing and optical coatings. Its strategy focuses on advancing its core platform through clinical validation, expanding into new biomarkers, and leveraging its state-of-the-art manufacturing and R&D facilities in Poland and the USA.

The inPROBE platform is a fiber-optic microsensor system that combines photonics and molecular biology for rapid, quantitative, point-of-care detection of protein biomarkers like HER2.

Competes with large diagnostic firms (Roche, Agilent) providing IHC/ISH kits and automated platforms, as well as companies developing rapid molecular POC systems. Differentiation lies in the real-time, label-free photonic sensing technology, but market penetration against established workflows is a formidable barrier.